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Abstract
The objective of this prospective study was to determine the plasma levels of nitric oxide (NO) in women with chronic pelvic
pain secondary to endometriosis (n=24) and abdominal myofascial pain syndrome (n=16). NO levels were measured in
plasma collected before and 1 month after treatment. Pretreatment NO levels (mM) were lower in healthy volunteers
(47.0±12.7) than in women with myofascial pain (64.2±5.0, P=0.01) or endometriosis (99.5±12.9, P,0.0001). After
treatment, plasma NO levels were reduced only in the endometriosis group (99.5±12.9 vs 61.6±5.9, P=0.002). A correlation
between reduction of pain intensity and reduction of NO level was observed in the endometriosis group [correlation = 0.67
(95%CI = 0.35 to 0.85), P,0.0001]. Reduction of NO levels was associated with an increase of pain threshold in this group
[correlation = –0.53 (–0.78 to –0.14), P,0.0001]. NO levels appeared elevated in women with chronic pelvic pain diagnosed
as secondary to endometriosis, and were directly associated with reduction in pain intensity and increase in pain threshold after
treatment. Further studies are needed to investigate the role of NO in the pathophysiology of pain in women with endometriosis
and its eventual association with central sensitization.
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Introduction
Chronic pelvic pain (CPP) is a highly prevalent (2 to 25%)
clinical problem among women (1). It is described as con-
tinuous or intermittent pain in the anatomic pelvis (anterior
abdominal wall at or below the umbilicus) that lasts at least 6
months, is not exclusively related to menstruation or sexual
intercourse, and is sufficiently severe to cause functional
disability or to lead to medical care (2). Its etiology is often
unknown but may result from a complex interaction between
the gastrointestinal, urinary, gynecologic, musculoskeletal,
neurologic, and endocrine systems. It is also influenced
by psychological and sociocultural factors. Among women
seen at gynecology outpatient clinics, one of the diseases
most often associated with CPP is endometriosis.
Abdominal myofascial pain syndrome, characterized by
hyperirritable trigger points is another frequent underdiag-
nosed condition causing CPP, especially in countries where
the prevalence of cesarean section and other abdominal
surgeries is common (3).
Researchers, physicians, gynecologists and patients
believe that CPP can be caused by the endometriosis
lesions (4), but determining how the lesions cause CPP
has proved difficult. Various pathophysiological mech-
anisms have been proposed to explain the development
of myofascial pain syndromes, but little is known about the
cause of this condition. The chronic inflammatory response
in endometriosis has been identified as an important factor
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in the pathophysiology of the disease (5). Similarly, elevated
levels of inflammatorymediators have been reported in sites
close to or far from activemyofascial trigger points (6). Some
studies indicate a possible role for nitric oxide (NO) in the
pathogenesis of endometriosis (7). It is nowwell appreciated
that NO can act as a mediator and regulator of the inflam-
matory response (8) and of the modulation of nociception
at both the peripheral and the central level (9). Studies on
animals have demonstrated that NO enhances the sensi-
tivity of peripheral nociceptors (10) and can contribute to
hyperalgesia secondary to central sensitization (11). Most
studies have shown pronociceptive properties of NO in the
spinal cord. Nevertheless, NO has a dual role in pain path-
ways. There is also evidence of its antinociceptive and
analgesic effect, particularly when present at low concentra-
tions within the spinal cord (12). In addition to this direct anal-
gesic effect, it may also mediate the peripheral and central
antinociceptive effect of other analgesic compounds (e.g.,
opioids and NSAIDs) (9). In humans, intracutaneous NO
injection can evoke pain (13), and increased NO levels have
been detected in the plasma of patients with chronic pain
(14), temporomandibular joint disorders (15), chronic orofa-
cial pain (16), and bladder pain syndrome/interstitial cystitis
(17). Although it has been observed that greater amounts
of NO are present in the endometrial tissues of women with
endometriosis (7), no studies have investigated plasma
NO levels in women with CPP secondary to endometriosis,
nor has it been determined whether there are differences
between women with CPP and those with abdominal myo-
fascial pain syndrome. Thus, the objective of the present
study was to determine plasma NO levels in women with
CPP secondary to those conditions and to explore their
association with pain intensity and pain threshold.
Material and Methods
Study population
This prospective study was conducted in women of
reproductive age without infertility and with regular men-
strual cycles. The Ethics Committee of the Hospital das
Clı´nicas, Faculdade de Medicina de Ribeira˜o Preto, Univer-
sidade de Sa˜o Paulo approved the study (protocol #3502/
2007, national registry 0112.0.004.000-07). The study sam-
ples were obtained when all inclusion criteria were satisfied
and written informed consent was obtained. The research
subjects were women with CPP and treated at the Gyne-
cologic Endoscopy and Chronic Pelvic Pain Center of the
same institution. Data from healthy control women during
routine gynecological follow-up were matched with the
study subjects by date of blood collection, age and parity,
and were obtained from a database of primary health care
unit records maintained by the university.
We selected 25 healthy subjects and 40womenwith CPP
without previous treatment. Women with CPP were divided
into 2 groups. Group 1 included 24 women diagnosed with
endometriosis confirmed by histology and classified during
laparoscopy according to the American Society for Re-
productive Medicine (18) as moderate (n=14) or severe
(n=10). Women with intestinal, bladder, or rectovaginal
septum invasion by endometriosis, as well as women with
minimal or mild endometriosis because of extensive surgery
or lack of histologic confirmation, respectively, were exclud-
ed from the study. Group 2 included 16 women diagnosed
exclusively with abdominal myofascial pain syndrome (19).
The study thus included a healthy control group, an endo-
metriosis group, and a myofascial group. Subjects with a
history of inflammation including fever, a history of acute
diseases such as flu; chronic diseases such as rheumatoid
arthritis, lupus, asthma, and allergic reactions; hypertension,
smoking habit, alcoholism, using hormonal contraceptives,
or without an imputable cause for CPP, were also excluded
(Figure 1).
Procedures
Women with endometriosis underwent laparoscopy
under general anesthesia and with pneumoperitoneum
obtained using carbon dioxide. Judicious inspection of the
abdominopelvic cavity was performed before any other
procedures were carried out. Endometriotic lesions were
classified according to the American Society of Repro-
ductive Medicine classification system (18). Electrosurgical
ablation and/or excision of superficial lesions that were
identified, removal of deep lesions, and/or cystectomy for
endometriomas were performed. All women underwent
conservative surgery, preserving the ovaries.
The diagnosis of abdominal myofascial pain syndrome
was clinically confirmed by Simons’ criteria (19). All women
with this syndrome were examined by abdominal wall ultra-
sound in order to exclude any other local conditions such as
hernias or abdominal wall cystic endometriosis.Womenwith
signs of ilioinguinal/iliohypogastric/genitofemoral neuropa-
thies were excluded. No women in this group presented with
significant dysmenorrhea. As specified in our service pro-
tocol, all women in the myofascial group received injections
of 2 mL 0.5% lidocaine (20), without a vasoconstrictor,
directly in and perpendicular to the trigger point at 5 weekly
sessions.
Pain measurement
Pain was quantified using a visual analogue scale (VAS)
before and after treatment; the McGill pain questionnaire
was applied only before treatment (21). We considered
the reduction of pain to be clinically relevant when subjects
showed a 50% reduction in the VAS, or at least a 20 mm
change with significant improvement reported in daily
activities (22).
The pressure pain threshold (i.e., the minimal pressure
that induced pain) was assessed with an Instrutherm DD-
500 pressure algometer with digital traction and compres-
sion and ameasuring capacity of 5 kg (Digital Dynamometer,
Model: DD200, Serial No. 08030300338819, InstruthermMea-
suring Instruments Ltd., Brazil). The apparatus consisted of
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a 1-cm diameter rubber disk attached to the plunger of
a pressure (force) gauge. The dial of the gauge was
calibrated in kg/cm2. We routinely measured the threshold
at a single point on the thenar region of the nondominant
hand. Three consecutive measurements were taken with
an interval of 20 min and the means were used in the
analysis. The Hospital Anxiety and Depression Scale
(23,24) was also used as a psychometric instrument.
NO measurement
Blood samples were obtained from women in the folli-
cular phase of the menstrual cycle (fifth to ninth day)
between 7:00 and 9:00 am (25). The first sample was
collected immediately before treatment and the second at 4
weeks after treatment. Subjects whose data were included
in the database were routinely contacted by phone 3 to 4
days before the collection and advised about diet (to avoid
foods such as meats in excessive amounts, coffee, teas,
chocolates, spices, pepper, salt, among others) and drug
intake (to avoid analgesics and nonsteroidal anti-inflamma-
tory drugs). Plasma samples were stored at –706C until
nitrate was assayed by the Griess colorimetric reaction (26).
Nitrite (NO2) plus nitrate (NO3) levels were determined
in plasma samples by enzymatically reducing nitrate with
bacterial nitrate reductase. Briefly, duplicate plasma sam-
ples (40 mL) were incubated overnight at 376Cwith an equal
volume of reductase buffer (0.5 M potassium phosphate,
pH 7.5, containing NADPH and nitrate reductase). The total
amount of nitrate was then determined by the colorimetric
Griess reaction. Briefly, samples were incubated with 80 mL
freshly prepared Griess reagent (2% sulphanylamide in 5%
phosphoric acid and 0.2% naphthylethylenediamine dihy-
drochloride). After 15 min of color development at room
temperature, the sample absorbance at 540 nm was com-
pared with values on a standard nitrate curve. The results
are reported as mM NO3+NO2.
Statistical analysis
Comparisons of NO levels between groups were per-
formed using the nonparametric Wilcoxon test for each
pair. The Wilcoxon signed rank test was used to compare
NO between pre- and post-treatment samples. Correlations
between NO, VAS, and pain threshold were evaluated by
the multivariate restricted maximum likelihood method. For
that analysis, we defined pain intensity variation (DVAS) as
(post-treatment VAS–pretreatment VAS)/pretreatment
VAS) NO level variation (DNO) was (post-treatment NO–
pretreatment NO)/pretreatment NO. Pain threshold varia-
tion (Dthreshold) was (post-treatment threshold–pretreat-
ment threshold)/pretreatment threshold). A negative sign
was used to indicate a reduction of measured value. The
statistical tests and plots were performed using JMP 10
statistical software for Mac (SAS Institute, USA) with the
level of significance set at P,0.05.
Results
The characteristics of the study participants are pre-
sented in Table 1. There was a clinically relevant reduction
of pain in 91.7% (n=22/24) of women with endometriosis
and 75.0% (n=12/16) of women with abdominal myofascial
pain syndrome. Pretreatment NO levels (mM) were lower in
Figure 1. Flow diagram of the recruitment of
subjects and samples.
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healthy volunteers (47.0±12.7) than in the myofascial
(64.2±5.0, P=0.01) or endometriosis (99.5±12.9, P,
0.0001) groups. The latter group had higher pretreatment
NO levels than the myofascial group (P =0.005).
The pain thresholds (kg/cm2) of healthy women (2.6±
0.2) were significantly higher than those of womenwith endo-
metriosis (1.0±0.1, P,0.0001) or myofascial syndrome
(1.9±0.2, P=0.007). This last group had higher pretreat-
ment pain thresholds than the group of women with endo-
metriosis (P=0.0004).
There was a reduction of plasma NO levels after treat-
ment in the endometriosis group (99.5±12.9 vs 61.6±5.9,
P=0.002), but not in the myofascial group (64.2±5.0 vs
61.1±8.2; P=0.70). No differences were observed in post-
treatment NO levels between the study groups and controls
even though the analysis had sufficient power to demon-
strate it (P=0.09). Table 2 shows post-treatment data
regarding the VAS pain intensity, pain threshold and NO
levels in the endometriosis and myofascial groups.
We observed a correlation between DVAS and DNO
level in the endometriosis group [correlation= 0.67 (95%CI:
0.35 to 0.85), P,0.0001], but not in the myofascial group
[correlation = –0.64 (–0.89 to 0.10), P=0.20]. We also
observed a correlation betweenDthreshold andDNO level in
the endometriosis group [correlation = –0.53 (–0.78 to
–0.14), P,0.0001] but not in the myofascial group [correla-
tion = –0.12 (–0.65 to 0.49), P=0.88].
Discussion
The present study showed that women with CPP secon-
dary to endometriosis had significantly elevated plasma NO
levels compared with healthy controls and women with CPP
secondary to abdominal myofascial pain syndrome. Clinical
improvement of CCP after surgical treatment of endome-
triosis was associated with a reduction of plasma NO levels.
However, these findings were not observed in women
with myofascial syndrome. This suggests that ablation or
excision of endometriosis may be responsible for reducing
peripheral levels of NO. Indeed, injection of anesthetic
into myofascial syndrome trigger points does not eliminate
the injury and probably only modulates the afferents. Addi-
tionally, we observed that NO reduction in women with
endometriosis was directly associated with reduction of
pain threshold, suggesting that NO may be involved in the
process of central sensitization. Interestingly, NO levels
did not reach those seen in healthy women, even after
appropriate treatment of their condition. It is possible that
Table 1. Characteristics of the subjects included in the study.
Parameters Healthy (n=25) Endometriosis (n=24) Myofascial (n=16) P
Age (years) 35.4 ± 6.7 32.9 ± 9.0 32.7 ± 7.8 0.37
Parity (median, range) 1 (0-5) 1.5 (0-11) 1 (0-4) 0.30
BMI 25.0 ± 3.3 25.6 ± 5.9 26.1 ± 3.4 0.66
HAD-anxiety 6.4 ± 4.1 9.6 ± 5.0 10.1 ± 6.9 0.09
.8 (n, %) 6 (24.0) 12 (50.0) 5 (31.2) 0.15
HAD-depression 6.5 ± 5.0 8.3 ± 4.6 10.8 ± 6.7 0.13
.9, n (%) 7 (28.0) 8 (33.3) 5 (31.2) 0.92
Duration of pain, months – 37.2 ± 31.7 40.6 ± 28.2 0.54
6 to 12 months, n (%) – 7 (29.2) 2 (12.4)
12 to 24 months, n (%) – 4 (16.7) 3 (18.8)
.24 months, n (%) – 13 (54.2) 11 (68.8)
VAS – 79.5 ± 15.4 85.9 ± 11.0 0.21
McGill – 33.3 ± 14.8 29.6 ± 16.2 0.51
Red blood cells 4.6 ± 0.3 4.7 ± 0.4 4.5 ± 0.3 0.55
Hematocrit 40.5 ± 2.9 41.4 ± 3.8 39.9 ± 2.8 0.30
Hemoglobin 13.4 ± 1.0 13.7 ± 1.3 13.2 ± 0.9 0.30
White blood cells 7.9 ± 2.3 7.4 ± 3.0 6.8 ± 1,1 0.20
Neutrophils 56.3 ± 11.0 57.8 ± 11.0 58.9 ± 8.4 0.87
Lymphocytes 33.0 ± 9.2 32.1 ± 8.9 32.3 ± 7.7 0.98
Eosinophils 3.4 ± 3.0 2.6 ± 2.1 1.6 ± 0.7 0.03
Basophils 0.6 ± 0.3 0.7 ± 0.4 0.8 ± 0.5 0.51
Monocytes 6.5 ± 3.1 6.6 ± 2.3 6.4 ± 1.8 0.89
Platelets 261.7 ± 51.3 269.5 ± 60.8 254.9 ± 50.3 0.97
Data are reported as means±SD unless otherwise indicated. BMI: body mass index; HAD: Hospital Anxiety and Depression Scale;
VAS: visual analogue scale, in millimeters; SD: standard deviation. The Wilcoxon and chi-squared tests were used for the statistical
analyses.
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other, particularly central, pathophysiological events may
be associated with the origin of NO, but our study does not
allow further evaluation.
Published studies have shown that NOmay be involved
in the pathophysiology of endometriosis. It has been ob-
served that NO synthesis is increased in endometrial tissue
from women with endometriosis (7), and changes have
been observed in endothelial nitric oxide synthase (eNOS)
expression in the endometrium of women with endome-
triosis (27,28) that can be associated with specific gene
polymorphisms of eNOS (29). However, eNOS has not
been involved in pain processing (30). Furthermore, a
significant increase in NO level was also detected in the
peritoneal fluid of women with endometriosis (19), probably
due to increased expression of inducible nitric oxide
synthase (iNOS) in peritoneal macrophages (31).
Most previous studies have focused on women with
infertility, and we did not find any that were specific to NO in
women with CPP. The association between NO and pain is
complex, but our results are similar to those reported by
some other authors (14,17). Under chronic pain conditions,
we know that the activation of N-methyl-D-aspartate
(NMDA) receptors in the spinal cord can produce persistent
enhancement of pain via production of NO and/or pros-
taglandins (32,33). There is also evidence that NO may
be directly involved in the process of central sensitiza-
tion following a painful stimulus (11,34). Our results (9,12)
suggest that this may be happening in women with CPP
secondary to endometriosis, since there was a positive
correlation between the reduction in plasma NO levels and
pain thresholds measured at a distance from the primary
site of pain. Moreover, it has been suggested that such a
mechanism might not be important in other conditions such
as abdominal myofascial pain syndrome.
Strengths and limitations of the study
The number of patients studied here was small, but the
inclusion criteria were very strict; thus we believe that
the data can be generalized with confidence. We recog-
nize, however, that an issue that might be questioned is the
interference of analgesic drugs, most commonly NSAIDs
(35). Although all women claimed that they had not taken
painkillers within the previous 3 or 4 days, this could not be
verified because they tended to deny this self-medication
behavior. In any case, the chronic anti-inflammatory action
of NSAIDsmay be due not only to inhibition of prostaglandin
synthesis but also through activation of arginine-NO-cGMP
pathways (36), inhibition of inducible nitric oxide synthase
gene expression, and NO synthesis (37). Thus, we would
have expected to detect lower NO levels in women with
CPP before treatment, which was not the case. Further, it
is known that neuronal nitric oxide synthase (nNOS) is
the most important enzyme in the spinal cord during both
development and maintenance of neuropathic and inflam-
matory pain (38,39). However, our study does not allow for
determining or making inferences about the origin of NO
identified peripherally.
Implications for future research or clinical practice
NO may represent an objective systemic marker of
reduced disease activity of endometriosis after treatment,
and perhaps of reduced central sensitization. Additionally,
the knowledge that inhibitors of nitric oxide synthase may
act as analgesic agents (40) opens an opportunity for their
use as a therapeutic target for this condition.
The present study does not permit us to make any
conclusions about the source of NO. It may be locally
produced in large amounts, and may reach the bloodstream
after washout from the interstitial space in the affected
region. The reasons are not entirely clear but it is known
that persistent activation of nociceptors results in activation
of the three known NO synthases, particularly inducible
and neuronal nitric oxide synthase, hence increasing NO
synthesis (14). On the other hand, we cannot explain why
this would not occur in women with abdominal myofascial
pain syndrome, and it is possible that, in women with CPP,
more NO is produced by the vascular system in response to
the prolonged and noncontinuous use of analgesic and/or
anti-inflammatory drugs (about 80% of our patients self-
medicate with these substances more than twice a week)
(3). Under these conditions, more NO would be produced
in endothelial cells to compensate for the inhibitory effect
of these analgesics. We consider this last hypothesis to
be less probable because, assuming the same rates of
self-medication, no difference would be expected between
groups.
In summary, NO levels were elevated in women with
CPP secondary to endometriosis, but not in women with
CPP secondary to abdominal myofascial pain syndrome.
Surgical treatment of endometriosis was associated with
Table 2. Intensity of pain, pain threshold and nitric oxide levels after treatment for both the endometriosis and myofascial groups.
Endometriosis (n=24) P Myofascial (n=16) P
Pre-treatment Post-treatment Pre-treatment Post-treatment
VAS (means±SD) 79.5 ± 15.4 30.8 ± 19.4 ,0.0001 85.9 ± 11.0 26.1 ± 5.7 ,0.001
Pain threshold (means±SE) 1.0 ± 0.1 1.3 ± 0.2 0.21 1.9 ± 0.2 1.7 ± 0.2 0.98
NO level (means±SE) 99.5 ± 12.9 61.6 ± 5.9 0.002 64.2 ± 5.0 61.1 ± 8.2 0.70
NO: nitric oxide; VAS: visual analogue scale, in millimeters. The Wilcoxon signed rank test was used for the statistical analyses.
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reduction in NO levels, which was correlated with a reduc-
tion in pain intensity and in distant pain thresholds. It is
possible that NO is involved in the pathophysiology of
pain secondary to endometriosis, possibly associated with
central sensitization. In our opinion, this correlation sup-
ports NO as a potential marker in patients with CPP and
endometriosis, a characteristic that has not been reported
previously.
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